Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis
Epistemonikos ID: c77f6926916a1a41ed8c296f15abd59b11fc436c
First added on: Mar 30, 2022